15 results on '"Rivella, Stefano"'
Search Results
2. Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease.
- Author
-
Akchurin, Oleh, Sureshbabu, Angara, Doty, Steve B., Yuan-Shan Zhu, Patino, Edwin, Cunningham-Rundles, Susanna, Choi, Mary E., Boskey, Adele, and Rivella, Stefano
- Subjects
PEDIATRIC nephrology ,GROWTH of children ,DWARFISM ,DISEASE risk factors - Abstract
Growth delay is common in children with chronic kidney disease (CKD), often associated with poor quality of life. The role of anemia in uremic growth delay is poorly understood. Here we describe an induction of uremic growth retardation by a 0.2% adenine diet in wild-type (WT) and hepcidin gene (Hamp) knockout (KO) mice, compared with their respective littermates fed a regular diet. Experiments were started at weaning (3 wk). After 8 wk, blood was collected and mice were euthanized. Adeninefed WT mice developed CKD (blood urea nitrogen 82.8 ± 11.6 mg/dl and creatinine 0.57 ± 0.07 mg/dl) and were 2.1 cm shorter compared with WT controls. WT adenine-fed mice were anemic and had low serum iron, elevated Hamp, and elevated IL6 and TNF-α. WT adenine-fed mice had advanced mineral bone disease (serum phosphorus 16.9 ± 3.1 mg/dl and FGF23 204.0 ± 115.0 ng/ml) with loss of cortical and trabecular bone volume seen on microcomputed tomography. Hamp disruption rescued the anemia phenotype resulting in improved growth rate in mice with CKD, thus providing direct experimental evidence of the relationship between Hamp pathway and growth impairment in CKD. Hamp disruption ameliorated CKD-induced growth hormone-insulin-like growth factor 1 axis derangements and growth plate alterations. Disruption of Hamp did not mitigate the development of uremia, inflammation, and mineral and bone disease in this model. Taken together, these results indicate that an adenine diet can be successfully used to study growth in mice with CKD. Hepcidin appears to be related to pathways of growth retardation in CKD suggesting that investigation of hepcidin-lowering therapies in juvenile CKD is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Altered erythropoiesis and iron metabolism in carriers of thalassemia.
- Author
-
Guimarães, Jacqueline S., Cominal, Juçara G., Silva‐Pinto, Ana Cristina, Olbina, Gordana, Ginzburg, Yelena Z., Nandi, Vijay, Westerman, Mark, Rivella, Stefano, and Souza, Ana Maria
- Subjects
THALASSEMIA ,HEMOGLOBINOPATHY ,SYNDROMES ,HEPCIDIN ,ERYTHROPOIETIN ,IRON metabolism ,ERYTHROPOIESIS - Abstract
The thalassemia syndromes (α- and β-thalassemia) are the most common and frequent disorders associated with ineffective erythropoiesis. Imbalance of α- or β-globin chain production results in impaired red blood cell synthesis, anemia, and more erythroid progenitors in the blood stream. While patients affected by these disorders show definitive altered parameters related to erythropoiesis, the relationship between the degree of anemia, altered erythropoiesis, and dysfunctional iron metabolism has not been investigated in both α-thalassemia carriers ( ATC) and β-thalassemia carriers ( BTC). Here, we demonstrate that ATC have a significantly reduced hepcidin and increased soluble transferrin receptor levels but relatively normal hematological findings. In contrast, BTC have several hematological parameters significantly different from controls, including increased soluble transferrin receptor and erythropoietin levels. These changes in both groups suggest an altered balance between erythropoiesis and iron metabolism. The index s Tf R/log ferritin and (hepcidin/ferritin)/s Tf R are, respectively, increased and reduced relative to controls, proportional to the severity of each thalassemia group. In conclusion, we showed in this study, for the first time in the literature, that thalassemia carriers have altered iron metabolism and erythropoiesis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. Identification of erythroferrone as an erythroid regulator of iron metabolism.
- Author
-
Kautz, Léon, Jung, Grace, Valore, Erika V, Rivella, Stefano, Nemeth, Elizabeta, and Ganz, Tomas
- Subjects
HEMORRHAGE ,IRON in the body ,ERYTHROPOIESIS ,HEPCIDIN ,BETA-Thalassemia - Abstract
Recovery from blood loss requires a greatly enhanced supply of iron to support expanded erythropoiesis. After hemorrhage, suppression of the iron-regulatory hormone hepcidin allows increased iron absorption and mobilization from stores. We identified a new hormone, erythroferrone (ERFE), that mediates hepcidin suppression during stress erythropoiesis. ERFE is produced by erythroblasts in response to erythropoietin. ERFE-deficient mice fail to suppress hepcidin rapidly after hemorrhage and exhibit a delay in recovery from blood loss. ERFE expression is greatly increased in Hbb
th3/+ mice with thalassemia intermedia, where it contributes to the suppression of hepcidin and the systemic iron overload characteristic of this disease. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
5. Hepcidin and Hfe in iron overload in β-thalassemia.
- Author
-
Gardenghi, Sara, Ramos, Pedro, Follenzi, Antonia, Rao, Niva, Rachmilewitz, Eliezer A., Giardina, Patricia J., Grady, Robert W., and Rivella, Stefano
- Subjects
IRON in the body ,THALASSEMIA ,HEMOGLOBINOPATHY ,MACROPHAGES ,IRON metabolism - Abstract
Hepcidin (HAMP) negatively regulates iron absorption, degrading the iron exporter ferroportin at the level of enterocytes and macrophages. We showed that mice with β-thalassemia intermedia ( th3/+) have increased anemia and iron overload. However, their hepcidin expression is relatively low compared to their iron burden. We also showed that the iron metabolism gene Hfe is down-regulated in concert with hepcidin in th3/+ mice. These observations suggest that low hepcidin levels are responsible for abnormal iron absorption in thalassemic mice and that down-regulation of Hfe might be involved in the pathway that controls hepcidin synthesis in β-thalassemia. Therefore, these studies suggest that increasing hepcidin and/or Hfe expression could be a strategy to reduces iron overload in these animals. The goal of this paper is to review recent findings that correlate hepcidin, Hfe, and iron metabolism in β-thalassemia and to discuss potential novel therapeutic approaches based on these recent discoveries. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
6. Iron metabolism and ineffective erythropoiesis in β-thalassemia mouse models.
- Author
-
Ramos, Pedro, Melchiori, Luca, Gardenghi, Sara, Van‐Roijen, Nico, Grady, Robert W., Ginzburg, Yelena, and Rivella, Stefano
- Subjects
THALASSEMIA ,ERYTHROPOIESIS ,GLOBIN genes ,IRON metabolism ,ANEMIA - Abstract
β-thalassemia is a disease associated with decreased β-globin production leading to anemia, ineffective erythropoiesis, and iron overload. New mechanisms associated with modulation of erythropoiesis and iron metabolism have recently been discovered in thalassemic mice, improving our understanding of the pathophysiology of this disease. These discoveries have the potential to be translated into clinically-relevant therapeutic options to reduce ineffective erythropoiesis and iron overload. A new generation of therapies based on limiting ineffective erythropoiesis, iron absorption, and the correction of iron maldistribution could be on the way, possibly complementing and improving the current standard of patient care. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
7. Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera.
- Author
-
Weizer-Stern, Orly, Adamsky, Konstantin, Amariglio, Ninette, Levin, Carina, Koren, Ariel, Breuer, William, Rachmilewitz, Eliezer, Breda, Laura, Rivella, Stefano, Ioav Cabantchik, Z., and Rechavi, Gideon
- Subjects
THALASSEMIA ,ERYTHROPOIESIS ,LIVER ,IRON metabolism ,HEPATOCELLULAR carcinoma ,PATIENTS - Abstract
β-Thalassaemia represents a group of diseases, in which ineffective erythropoiesis is accompanied by iron overload. In a mouse model of β-thalassaemia, we observed that the liver expressed relatively low levels of hepcidin, which is a key factor in the regulation of iron absorption by the gut and of iron recycling by the reticuloendothelial system. It was hypothesised that, despite the overt iron overload, a putative plasma factor found in β-thalassaemia might suppress liver hepcidin expression. Sera from β-thalassaemia and haemochromatosis (C282Y mutation) patients were compared with those of healthy individuals regarding their capacity to induce changes the expression of key genes of iron metabolism in human HepG2 hepatoma cells. Sera from β-thalassaemia major patients induced a major decrease in hepcidin ( HAMP) and lipocalin2 (oncogene 24p3) ( LCN2) expression, as well as a moderate decrease in haemojuvelin ( HFE2) expression, compared with sera from healthy individuals. A significant correlation was found between the degree of downregulation of HAMP and HFE2 induced by β-thalassaemia major sera ( r = 0·852, P < 0·0009). Decreased HAMP expression was also found in HepG2 cells treated with sera from β-thalassaemia intermedia patients. In contrast, the majority of sera from hereditary haemochromatosis patients induced an increase in HAMP expression, which correlated with transferrin (Tf) saturation ( r = 0·765, P < 0·0099). Our results suggest that, in β-thalassaemia, serum factors might override the potential effect of iron overload on HAMP expression, thereby providing an explanation for the failure to arrest excessive intestinal iron absorption in these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
8. Role of Iron in Inducing Oxidative Stress in Thalassemia: Can It Be Prevented by Inhibition of Absorption and by Antioxidants?
- Author
-
RACHMILEWITZ, ELIEZER A., WEIZER‐STERN, ORLY, ADAMSKY, KONSTANTIN, AMARIGLIO, NINETTE, RECHAVI, GIDEON, BREDA, LAURA, RIVELLA, STEFANO, and CABANTCHIK, Z IOAV
- Subjects
THALASSEMIA ,HEMOGLOBINOPATHY ,OXIDATIVE stress ,ANTIOXIDANTS ,ERYTHROCYTES ,RNA - Abstract
The pathophysiology of thalassemia is, to a certain extent, associated with the generation of labile iron in the pathological red blood cell (RBC). The appearance of such forms of iron at the inner and outer cell surfaces exposes the cell to conditions whereby the labile metal promotes the formation of reactive oxygen species (ROS) leading to cumulative cell damage. Another source of iron accumulation results from increased absorption due to decreased expression of hepcidin. The presence of labile plasma iron (LPI) was carried out using fluorescent probes in the FACS. RNA expression of hepcidin was measured in two models of thalassemic mice. Hepcidin expression was also measured in human hapatoma HepG2 cells following incubation with thalassemic sera. LPI was identified and could be quantitatively measured and correlated with other parameters of iron overload. Hepcidin expression was downregulated in the livers of thalassemic mice, in major more than in intermedia. Thalassemic sera down regulated hepcidin expression in HepG2 liver cells. A possible way to decrease iron absorption could be by modulating hepcidin expression pharmacologically, by gene therapy or by its administration. Treatment with combination of antioxidants such as N-acetylcysteine for proteins and vitamin E for lipids in addition to iron chelators could neutralize the deleterious effects of ROS and monitored by quantitation of LPI. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
9. Hepcidin agonists as therapeutic tools.
- Author
-
Casu, Carla, Nemeth, Elizabeta, and Rivella, Stefano
- Subjects
- *
HEPCIDIN , *PEPTIDE hormones , *IRON in the body , *HEMOCHROMATOSIS , *POLYCYTHEMIA vera , *BETA-Thalassemia , *THERAPEUTICS - Abstract
Hepcidin agonists are a new class of compounds that regulate blood iron levels, limit iron absorption, and could improve the treatment of hemochromatosis, b-thalassemia, polycythemia vera, and other disorders in which disrupted iron homeostasis causes or contributes to disease. Hepcidin agonists also have the potential to prevent severe complications of siderophilic infections in patients with iron overload or chronic liver disease. This review highlights the preclinical studies that support the development of hepcidin agonists for the treatment of these disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. The hepcidin regulator erythroferrone is a new member of the erythropoiesis-iron-bone circuitry.
- Author
-
Castro-Mollo, Melanie, Gera, Sakshi, Ruiz-Martinez, Marc, Feola, Maria, Gumerova, Anisa, Planoutene, Marina, Clementelli, Cara, Sangkhae, Veena, Casu, Carla, Se-Min Kim, Ostland, Vaughn, Huiling Han, Nemeth, Elizabeta, Fleming, Robert, Rivella, Stefano, Lizneva, Daria, Yuen, Tony, Zaidi, Mone, and Ginzburg, Yelena
- Subjects
- *
BONE morphogenetic proteins , *HEPCIDIN , *BONE growth , *SCLEROSTIN , *TRANCE protein - Abstract
Background: Erythroblast erythroferrone (ERFE) secretion inhibits hepcidin expression by sequestering several bone morphogenetic protein (BMP) family members to increase iron availability for erythropoiesis. Methods: To address whether ERFE functions also in bone and whether the mechanism of ERFE action in bone involves BMPs, we utilize the Erfe -/-mouse model as well as β-thalassemic (Hbbth3/+) mice with systemic loss of ERFE expression. In additional, we employ comprehensive skeletal phenotyping analyses as well as functional assays in vitro to address mechanistically the function of ERFE in bone. Results: We report that ERFE expression in osteoblasts is higher compared with erythroblasts, is independent of erythropoietin, and functional in suppressing hepatocyte hepcidin expression. Erfe-/-mice display low-bone-mass arising from increased bone resorption despite a concomitant increase in bone formation. Consistently, Erfe-/- osteoblasts exhibit enhanced mineralization, Sost and Rankl expression, and BMP-mediated signaling ex vivo. The ERFE effect on osteoclasts is mediated through increased osteoblastic RANKL and sclerostin expression, increasing osteoclastogenesis in Erfe-/- mice. Importantly, Erfe loss in HbbtH3/+mice, a disease model with increased ERFE expression, triggers profound osteoclastic bone resorption and bone loss. Conclusions: Together, ERFE exerts an osteoprotective effect by modulating BMP signaling in osteoblasts, decreasing RANKL production to limit osteoclastogenesis, and prevents excessive bone loss during expanded erythropoiesis in β-thalassemia. Funding: YZG acknowledges the support of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 DK107670 to YZG and DK095112 to RF, SR, and YZG). MZ acknowledges the support of the National Institute on Aging (U19 AG60917) and NIDDK (R01 DK113627). TY acknowledges the support of the National Institute on Aging (R01 AG71870). SR acknowledges the support of NIDDK (R01 DK090554) and Commonwealth Universal Research Enhancement (CURE) Program Pennsylvania. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.
- Author
-
Aschemeyer, Sharraya, Qiao, Bo, Stefanova, Deborah, Valore, Erika V., Sek, Albert C., Ruwe, T. Alex, Vieth, Kyle R., Jung, Grace, Casu, Carla, Rivella, Stefano, Jormakka, Mika, Mackenzie, Bryan, Ganz, Tomas, and Nemeth, Elizabeta
- Subjects
- *
HEPCIDIN , *HEMOCHROMATOSIS , *GENETIC disorders , *GENE mapping , *GENETIC mutation , *PATIENTS - Abstract
Nonclassical ferroportin disease (FD) is a form of hereditary hemochromatosis caused by mutations in the iron transporter ferroportin (Fpn), resulting in parenchymal iron overload. Fpn is regulated by the hormone hepcidin, which induces Fpn endocytosis and cellular iron retention. We characterized 11 clinically relevant and 5 nonclinical Fpn mutations using stably transfected, inducible isogenic cell lines. All clinical mutants were functionally resistant to hepcidin as a consequence of either impaired hepcidin binding or impaired hepcidin-dependent ubiquitination despite intact hepcidin binding. Mapping the residues onto 2 computational models of the human Fpn structure indicated that (1) mutations that caused ubiquitination-resistance were positioned at helix-helix interfaces, likely preventing the hepcidin-induced conformational change, (2) hepcidin binding occurred within the central cavity of Fpn, (3) hepcidin interacted with up to 4 helices, and (4) hepcidin binding should occlude Fpn and interfere with iron export independently of endocytosis. We experimentally confirmed hepcidin-mediated occlusion of Fpn in the absence of endocytosis in multiple cellular systems: HEK293 cells expressing an endocytosis-defective Fpn mutant (K8R), Xenopus oocytes expressing wild-type or K8R Fpn, and mature human red blood cells.Weconclude that nonclassical FD is caused by Fpn mutations that decrease hepcidin binding or hinder conformational changes required for ubiquitination and endocytosis of Fpn. The newly documented ability of hepcidin and its agonists to occlude iron transport may facilitate the development of broadly effective treatments for hereditary iron overload disorders. (Blood. 2018;131(8):899-910) [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice.
- Author
-
Huihui Li, Tenzin Choesang, Weili Bao, Huiyong Chen, Feola, Maria, Garcia-Santos, Daniel, Jie Li, Shuming Sun, Follenzi, Antonia, Pham, Petra, Jing Liu, Jinghua Zhang, Prem Ponka, Xiuli An, Mohandas, Narla, Fleming, Robert E., Rivella, Stefano, Guiyuan Li, and Ginzburg, Yelena Z.
- Subjects
- *
HEPCIDIN , *ERYTHROPOIESIS , *TRANSFERRIN , *RETICULOCYTES , *LABORATORY mice - Abstract
Iron availability for erythropoiesis and its dysregulation in β-thalassemia are incompletely understood. We previously demonstrated that exogenous apotransferrin leads to more effective erythropoiesis, decreasing erythroferrone (ERFE) and derepressing hepcidin in β-thalassemic mice. Transferrin-bound iron binding to transferrin receptor 1 (TfR1) is essential for cellular iron delivery during erythropoiesis. We hypothesize that apotransferrin's effect is mediated via decreased TfR1 expression and evaluate TfR1 expression in β-thalassemic mice in vivo and in vitro with and without added apotransferrin. Our findings demonstrate that β-thalassemic erythroid precursors overexpress TfR1, an effect that can be reversed by the administration of exogenous apotransferrin. In vitro experiments demonstrate that apotransferrin inhibits TfR1 expression independent of erythropoietin- and iron-related signaling, decreases TfR1 partitioning to reticulocytes during enucleation, and enhances enucleation of defective β-thalassemic erythroid precursors. These findings strongly suggest that overexpressed Tf R1 may play a regulatory role contributing to iron overload and anemia in β-thalassemic mice. To evaluate further, we crossed TfR1+/- mice, themselves exhibiting iron-restricted erythropoiesis with increased hepcidin, with β-thalassemic mice. Resultant double-heterozygote mice demonstrate long-term improvement in ineffective erythropoiesis, hepcidin derepression, and increased erythroid enucleation in relation to β-thalassemic mice. Our data demonstrate for the first time that TfR1+/- haploinsufficiency reverses iron overload specifically in β-thalassemic erythroid precursors. Taken together, decreasing TfR1 expression during β-thalassemic erythropoiesis, either directly via induced haploinsufficiency or via exogenous apotransferrin, decreases ineffective erythropoiesis and provides an endogenous mechanism to upregulate hepcidin, leading to sustained iron-restricted erythropoiesis and preventing systemic iron overload in β-thalassemic mice. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. Distinct roles for hepcidin and interleukin-6 in the recovery from anemia in mice injected with heat-killed Brucella abortus.
- Author
-
Gardenghi, Sara, Renaud, Tom M., Meloni, Alessandra, Casu, Carla, Crielaard, Bart J., Bystrom, Laura M., Greenberg-Kushnir, Noa, Sasu, Barbra J., Cooke, Keegan S., and Rivella, Stefano
- Subjects
- *
ANEMIA , *HEPCIDIN , *INTERLEUKIN-6 , *LABORATORY mice , *BRUCELLA abortus , *ERYTHROPOIESIS , *IRON metabolism - Abstract
Anemia of inflammation (AI) is commonly observed in chronic inflammatory states and may hinder patient recovery and survival. Induction of hepcidin, mediated by interleukin 6, leads to iron-restricted erythropoiesis and anemia. Several translational studies have been directed at neutralizing hepcidin overexpression as a therapeutic strategy against AI. However, additional hepcidin-independent mechanisms contribute to AI, which are likely mediated by a direct effect of inflammatory cytokines on erythropoiesis. In this study, we used wild-type, hepcidin knockout (Hamp-KO) and interleukin 6 knockout (IL-6-KO) mice as models of AI. AI was induced with heat-killed Brucella abortus (BA). The distinct roles of iron metabolism and inflammation triggered by interleukin 6 and hepcidin were investigated. BA-treated wild-type mice showed increased expression of hepcidin and inflammatory cytokines, as well as transitory suppression of erythropoiesis and shortened red blood cell lifespan, all of which contributed to the severe anemia of these mice. In contrast, BA-treated Hamp-KO or IL-6-KO mice showed milder anemia and faster recovery compared with normal mice. Moreover, they exhibited different patterns in the development and resolution of anemia, supporting the notion that interleukin 6 and hepcidin play distinct roles in modulating erythropoiesis in AI. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
14. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice.
- Author
-
Shuling Guo, Casu, Carla, Gardenghi, Sara, Booten, Sheri, Aghajan, Mariam, Peralta, Raechel, Watt, Andy, Freier, Sue, Monia, Brett P., and Rivella, Stefano
- Subjects
- *
THALASSEMIA , *HEMOCHROMATOSIS , *HEPCIDIN , *IRON , *SERINE proteinases , *OLIGONUCLEOTIDES , *LABORATORY mice , *ERYTHROPOIETIN - Abstract
β-Thalassemia and HFE-related hemochromatosis are 2 of the most frequently inherited disorders worldwide. Both disorders are characterized by low levels of hepcidin (HAMP), the hormone that regulates iron absorption. As a consequence, patients affected by these disorders exhibit iron overload, which is the main cause of morbidity and mortality. HAMP expression is controlled by activation of the SMAD1,5,8/SMAD4 complex. TMPRSS6 is a serine protease that reduces SMAD activation and blocks HAMP expression. We identified second generation antisense oligonucleotides (ASOs) targeting mouse Tmprss6. ASO treatment in mice affected by hemochromatosis (Hfe-/-) significantly decreased serum iron, transferrin saturation and liver iron accumulation. Furthermore, ASO treatment of mice affected by β-thalassemia (HBBth3/+ mice, referred to here after as th3/+ mice) decreased the formation of insoluble membrane-bound globins, ROS, and apoptosis, and improved anemia. These animals also exhibited lower erythropoietin levels, a significant amelioration of ineffective erythropoiesis (IE) and splenomegaly, and an increase in total hemoglobin levels. These data suggest that ASOs targeting Tmprss6 could be beneficial in individuals with hemochromatosis, β-thalassemia, and related disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
15. Decreased hepcidin expression in murine ß-thalassemia is associated with suppression of Bmp/Smad signaling.
- Author
-
Parrow, Nermi L., Gardenghi, Sara, Ramos, Pedro, Casu, Carla, Grady, Robert W., Anderson, Erik R., Shah, Yatrik M., Li, Huihui, Ginzburg, Yelena Z., Fleming, Robert E., and Rivella, Stefano
- Subjects
- *
GENETICS of thalassemia , *HEPCIDIN , *BONE morphogenetic proteins , *HEMOGLOBINS , *ERYTHROPOIESIS , *ERYTHROCYTE membranes - Abstract
The article discusses a study on the association of decreased hepcidin expression in murine β-thalassemia with the suppression of bone morphogenetic protein (Bmp) and Smad signaling. It informs that β-thalassemia is a genetic disorder of hemoglobin production in which ineffective erythropoiesis and anemia takes place. It also informs that different erythroid signals regulate hepcidin in normal and ineffective erythropoiesis.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.